US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aspire Biopharma Holdings Inc.

0.0999

+0.00111.11%

Post-market: 0.10240.0025+2.50%18:20 EST

Volume:27.53M

Turnover:2.89M

Market Cap:10.74M

PE:-0.24

High:0.1090

Open:0.1090

Low:0.0988

Close:0.0988

52wk High:15.80

52wk Low:0.0880

Shares:107.48M

Float Shares:35.35M

Volume Ratio:2.25

T/O Rate:77.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4147

EPS(LYR):-0.0030

ROE:--

ROA:-195.11%

PB:-0.94

PE(LYR):-33.57

Loading ...

Overview Company News Filings

Aspire Biopharma Secures $9.7M Securities Purchase Agreement with Investors

Aspire Biopharma Holdings Inc. Unveils Investor Presentation Highlighting Patent-Pending Sublingual Drug Delivery Technology

Top Midday Gainers

MT Newswires Live

Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August

Aspire Biopharma Announces Positive Results from Clinical Trial of New Sublingual Aspirin for Heart Attack Treatment

Aspire Biopharma Holdings Inc. to Present at Sidoti Virtual Investor Conference

Aspire Biopharma Hldgs Q2 EPS $(0.04)

Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Annual Report

Aspire Biopharma Holdings Inc. to Attend Major Fitness Conventions FitCon and FitExpo for BUZZ BOMB™ Launch

Aspire Biopharma Holdings Inc: Michael Howe Has Resigned as CEO

THOMSON REUTERS

Aspire Biopharma Appoints Kraig Higginson as Interim CEO and Howard Doss as Chairman of Audit Committee Following Leadership Resignations

Aspire Biopharma Holdings Inc. to Launch BUZZ BOMB Pre-Workout Supplement at Major Fitness Conventions, FitCon and FitExpo

Aspire Biopharma Holdings Inc. to Debut BUZZ BOMB™ at Major Fitness Conventions FITCON and Fit Expo

Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025

Aspire Biopharma Holdings Inc. Unveils Investor Presentation Highlighting Innovative Sublingual Drug Delivery Technology

Aspire Biopharma Holdings Inc. Appoints Michael C. Howe as New CEO, Succeeding Kraig Higginson

Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ASBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":0.0999,"timestamp":1764709200000,"preClose":0.0988,"halted":0,"volume":27525194,"hourTrading":{"tag":"盘后","latestPrice":0.1024,"preClose":0.0999,"latestTime":"18:20 EST","volume":768914,"amount":78575.44468624001,"timestamp":1764717635093},"delay":0,"floatShares":35345600,"shares":107477178,"eps":-0.414708,"marketStatus":"Post-Mkt","change":0.0011,"latestTime":"12-02 18:21:06 EST","open":0.109,"high":0.109,"low":0.0988,"amount":2894709.0471652,"amplitude":0.103239,"askPrice":0.107,"askSize":4500,"bidPrice":0.1,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.414708,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0988,"preHourTrading":{"tag":"盘前","latestPrice":0.1077,"preClose":0.0988,"latestTime":"09:29 EST","volume":5912568,"amount":634147.3073430001,"timestamp":1764685793213},"postHourTrading":{"tag":"盘后","latestPrice":0.1024,"preClose":0.0999,"latestTime":"18:20 EST","volume":768914,"amount":78575.44468624001,"timestamp":1764717635093},"volumeRatio":2.246299},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","floatShares":35345600,"roa":"-195.11%","roe":"--","lyrEps":-0.002976,"volumeRatio":2.246299,"shares":107477178,"dividePrice":0,"high":0.109,"amplitude":0.103239,"preClose":0.0988,"low":0.0988,"week52Low":0.088,"pbRate":"-0.94","psRate":"5531.67","week52High":15.8,"institutionHeld":0,"latestPrice":0.0999,"committee":-0.384615,"eps":-0.414708,"divideRate":0,"volume":27525194,"delay":0,"ttmEps":-0.414708,"open":0.109,"prevYearClose":11.5,"prevWeekClose":0.1057,"prevMonthClose":0.1057,"prevQuarterClose":0.206,"fiveDayClose":0.1,"twentyDayClose":0.3617,"sixtyDayClose":0.5117},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASBP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASBP","date":"2025-12-01","current":-0.23824,"percent":0.925926,"low":-107.647863,"twenty":-32.753656,"median":-1.10471,"eighty":-0.838948,"high":-0.235902,"avg":-12.267175,"sd":19.66125,"marketCap":11360337},"quantilePoints":[{"date":"2025-03-07","current":-61.718107,"twenty":-79.515888,"median":-61.718107,"eighty":-58.474317,"marketCap":40003023},{"date":"2025-03-14","current":-41.62384,"twenty":-63.871064,"median":-57.344015,"eighty":-54.828644,"marketCap":26978783},{"date":"2025-03-21","current":-49.388839,"twenty":-61.718107,"median":-55.259235,"eighty":-45.464716,"marketCap":32011722},{"date":"2025-03-28","current":-47.36506,"twenty":-59.766092,"median":-48.376949,"eighty":-45.613987,"marketCap":30699995},{"date":"2025-04-04","current":-38.75323,"twenty":-56.183571,"median":-46.367595,"eighty":-43.647619,"marketCap":25118177},{"date":"2025-04-11","current":-38.035578,"twenty":-55.34679,"median":-45.929755,"eighty":-40.946376,"marketCap":24653026},{"date":"2025-04-17","current":-39.57853,"twenty":-55.287942,"median":-45.474044,"eighty":-39.546954,"marketCap":25653101},{"date":"2025-04-25","current":-36.428037,"twenty":-53.967461,"median":-44.487272,"eighty":-38.006872,"marketCap":23611087},{"date":"2025-05-02","current":-25.763721,"twenty":-50.875815,"median":-42.879731,"eighty":-36.06634,"marketCap":16698936},{"date":"2025-05-09","current":-24.070062,"twenty":-48.174572,"median":-41.62384,"eighty":-32.456117,"marketCap":15601179},{"date":"2025-05-16","current":-8.64997,"twenty":-47.360753,"median":-40.170558,"eighty":-27.896584,"marketCap":11330354},{"date":"2025-05-23","current":-0.643502,"twenty":-46.76371,"median":-38.75323,"eighty":-25.110657,"marketCap":10952545},{"date":"2025-05-30","current":-1.730761,"twenty":-46.192459,"median":-37.963813,"eighty":-23.557658,"marketCap":29457944},{"date":"2025-06-06","current":-0.976857,"twenty":-45.929755,"median":-36.514155,"eighty":-4.677726,"marketCap":16626329},{"date":"2025-06-13","current":-1.091781,"twenty":-45.929755,"median":-34.956848,"eighty":-1.13913,"marketCap":18582368},{"date":"2025-06-20","current":-0.913361,"twenty":-45.88526,"median":-32.509654,"eighty":-1.103849,"marketCap":15545618},{"date":"2025-06-27","current":-0.879171,"twenty":-45.613987,"median":-30.966702,"eighty":-1.056614,"marketCap":14963696},{"date":"2025-07-03","current":-0.838948,"twenty":-45.240807,"median":-27.672677,"eighty":-0.926003,"marketCap":14279083},{"date":"2025-07-11","current":-0.994957,"twenty":-44.49445,"median":-25.763721,"eighty":-0.89957,"marketCap":16934405},{"date":"2025-07-18","current":-1.022827,"twenty":-44.487272,"median":-24.235121,"eighty":-0.913361,"marketCap":17408745},{"date":"2025-07-25","current":-1.492005,"twenty":-43.705031,"median":-23.47441,"eighty":-0.913361,"marketCap":25394273},{"date":"2025-08-01","current":-1.094942,"twenty":-43.417971,"median":-12.855253,"eighty":-0.926003,"marketCap":18636159},{"date":"2025-08-08","current":-0.957894,"twenty":-42.341491,"median":-1.730761,"eighty":-0.926003,"marketCap":16303583},{"date":"2025-08-15","current":-1.119076,"twenty":-41.810429,"median":-1.408829,"eighty":-0.936633,"marketCap":19046927},{"date":"2025-08-22","current":-1.407348,"twenty":-41.62384,"median":-1.381965,"eighty":-0.948126,"marketCap":26605351},{"date":"2025-08-29","current":-1.458172,"twenty":-41.494663,"median":-1.401585,"eighty":-0.950712,"marketCap":27566154},{"date":"2025-09-05","current":-1.427258,"twenty":-40.909001,"median":-1.428961,"eighty":-0.956458,"marketCap":26981748},{"date":"2025-09-12","current":-1.182832,"twenty":-39.815341,"median":-1.395821,"eighty":-0.96387,"marketCap":22360975},{"date":"2025-09-19","current":-1.153491,"twenty":-39.515377,"median":-1.375367,"eighty":-0.974558,"marketCap":21806284},{"date":"2025-09-26","current":-0.990278,"twenty":-38.902502,"median":-1.341067,"eighty":-0.987594,"marketCap":18720816},{"date":"2025-10-03","current":-1.100309,"twenty":-38.179108,"median":-1.232741,"eighty":-0.956458,"marketCap":20800907},{"date":"2025-10-10","current":-0.881819,"twenty":-37.978166,"median":-1.192915,"eighty":-0.950195,"marketCap":16670441},{"date":"2025-10-17","current":-0.836759,"twenty":-37.504515,"median":-1.176427,"eighty":-0.934507,"marketCap":15818594},{"date":"2025-10-24","current":-0.880247,"twenty":-36.758157,"median":-1.164494,"eighty":-0.913361,"marketCap":16640725},{"date":"2025-10-31","current":-0.986087,"twenty":-36.462484,"median":-1.14993,"eighty":-0.912711,"marketCap":18641575},{"date":"2025-11-07","current":-0.694243,"twenty":-35.704643,"median":-1.134878,"eighty":-0.909799,"marketCap":13124382},{"date":"2025-11-14","current":-0.275601,"twenty":-35.070237,"median":-1.124309,"eighty":-0.898954,"marketCap":5210132},{"date":"2025-11-21","current":-0.235902,"twenty":-33.9751,"median":-1.119076,"eighty":-0.881505,"marketCap":4838687},{"date":"2025-11-28","current":-0.553115,"twenty":-32.997658,"median":-1.106147,"eighty":-0.854611,"marketCap":11360337},{"date":"2025-12-01","current":-0.553115,"twenty":-32.753656,"median":-1.10471,"eighty":-0.838948,"marketCap":11360337}],"updateTime":1764683023974},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2561128351","title":"Aspire Biopharma Secures $9.7M Securities Purchase Agreement with Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2561128351","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561128351?lang=en_us&edition=fundamental","pubTime":"2025-08-23 05:15","pubTimestamp":1755897356,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings, Inc. recently announced the signing of a Securities Purchase Agreement with a group of investors. Under this agreement, Aspire Biopharma sold notes amounting to $9,687,500 for a subscription price of $7,750,000. The notes, which feature a 20% original issue discount and no interest rate, will mature on February 19, 2026. Additionally, the notes can be converted into common stock starting 31 days from issuance at 80% of the lowest closing price within the preceding five trading days. The company retains the option to prepay these notes at a 20% premium to the principal amount.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL1zks46:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2560112561","title":"Aspire Biopharma Holdings Inc. Unveils Investor Presentation Highlighting Patent-Pending Sublingual Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2560112561","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560112561?lang=en_us&edition=fundamental","pubTime":"2025-08-20 04:19","pubTimestamp":1755634775,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., listed on Nasdaq as ASBP, has released an investor presentation highlighting its innovative, patent-pending drug delivery technology. This technology is designed for rapid sublingual absorption, enhancing the pharmacokinetic performance of Active Pharmaceutical Ingredients , supplements, and nutraceuticals, increasing bioavailability and improving the speed of onset. Aspire's key products include a lead Rx product, Sublingual High Dose Aspirin, and a lead consumer product, BUZZ BOMB. The presentation emphasizes the company's focus on commercialization through partnerships, licensing, and internal development, with first revenues expected in late 2025. Aspire's market opportunity exceeds $100 billion, as it continues to develop disruptive technologies for fast-acting drug formulations. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL47Z0Qt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2560182419","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2560182419","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560182419?lang=en_us&edition=fundamental","pubTime":"2025-08-19 01:24","pubTimestamp":1755537882,"startTime":"0","endTime":"0","summary":"Soligenix  said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels.Shares surged 85% as intraday trading volume catapulted to more than 146.2 million from a daily average of about 8 million.Propanc Biopharma  shares soared 131% in heavy trading after midday on Monday following their debut on Nasdaq on Friday.More than 63.3 million shares traded intraday.Aspire Biopharma  said Monday its investigational sublingual aspirin product demonstrated \"higher and more rapid\" mean plasma concentrations of acetylsalicylic acid, compared with standard chewed aspirin tablets.Shares jumped 52%, with intraday trading volume at over 430.7 million from a daily average of about 15 million.Price: 6.63, Change: +3.76, Percent Change: +130.84","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PPCB","ASBP","SNGX","BK4139","BK4007"],"gpt_icon":0},{"id":"2560825041","title":"Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August","url":"https://stock-news.laohu8.com/highlight/detail?id=2560825041","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560825041?lang=en_us&edition=fundamental","pubTime":"2025-08-19 01:15","pubTimestamp":1755537313,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/08/47191981/crude-oil-moves-higher-us-homebuilder-sentiment-declines-in-august","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4091","USAW.SI","NVIW.SI","BK4539","USJW.SI","PSQ","TQQQ","BK4139","BK4583","PPCB","BK4023","BK4007","TSYW.SI","QLD","ASBP","NQmain","EMPD","QID","RSKD","GDRX",".IXIC","BK4167","MNQmain","SQQQ"],"gpt_icon":1},{"id":"2560907443","title":"Aspire Biopharma Announces Positive Results from Clinical Trial of New Sublingual Aspirin for Heart Attack Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560907443","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560907443?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:30","pubTimestamp":1755520251,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced positive top-line results from a recent clinical trial of their investigational sublingual aspirin product for the treatment of suspected acute myocardial infarction. The trial demonstrated that Aspire's sublingual aspirin provides a higher and more rapid therapeutic impact compared to standard chewed aspirin tablets. The product was found to be safe and well-tolerated in the study. Aspire plans to review these results with the FDA to potentially pursue accelerated approval. The clinical trial, AB-101, was a randomized crossover bioavailability study involving healthy adults, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the sublingual aspirin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL6mDT91:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2559765954","title":"Aspire Biopharma Holdings Inc. to Present at Sidoti Virtual Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2559765954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559765954?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:00","pubTimestamp":1755172828,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., a developer of multi-faceted patent-pending drug and supplement delivery technology, will be presenting at the Sidoti Virtual Investor Conference on August 20, 2025. Kraig Higginson, Interim CEO of Aspire, is scheduled to present at 1:45 PM Eastern. Additionally, the company will host virtual one-on-one meetings with investors on August 20 and 21.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL63nrsG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2559709984","title":"Aspire Biopharma Hldgs Q2 EPS $(0.04)","url":"https://stock-news.laohu8.com/highlight/detail?id=2559709984","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559709984?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:50","pubTimestamp":1755121808,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Hldgs (NASDAQ:ASBP) reported quarterly losses of $(0.04) per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47109522/aspire-biopharma-hldgs-q2-eps-0-04","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Aspire Biopharma Hldgs Q2 EPS $(0.04)","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP"],"gpt_icon":0},{"id":"2559843129","title":"Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2559843129","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559843129?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:01","pubTimestamp":1755118898,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has filed an amendment to the 10-Q annual report for the financial year ending March 31, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLb41YvC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2559075386","title":"Aspire Biopharma Holdings Inc. to Attend Major Fitness Conventions FitCon and FitExpo for BUZZ BOMB™ Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2559075386","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559075386?lang=en_us&edition=fundamental","pubTime":"2025-08-13 21:11","pubTimestamp":1755090665,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. successfully launched its BUZZ BOMB pre-workout supplement at two major fitness conventions, FitCon and FitExpo, held from August 1-3, 2025, in Salt Lake City and Anaheim. The company distributed over 30,000 sample packs of its sublingual pre-workout supplement, which features a rapid caffeine delivery system, at these events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLsZJ6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2555274180","title":"Aspire Biopharma Holdings Inc: Michael Howe Has Resigned as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2555274180","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555274180?lang=en_us&edition=fundamental","pubTime":"2025-07-31 05:32","pubTimestamp":1753911126,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nFWN3TR26F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2555274560","title":"Aspire Biopharma Appoints Kraig Higginson as Interim CEO and Howard Doss as Chairman of Audit Committee Following Leadership Resignations","url":"https://stock-news.laohu8.com/highlight/detail?id=2555274560","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555274560?lang=en_us&edition=fundamental","pubTime":"2025-07-31 05:29","pubTimestamp":1753910994,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Appoints Kraig Higginson as Interim CEO and Howard Doss as Chairman of Audit Committee Following Leadership Resignations. Aspire Biopharma Holdings Inc. announced that Michael Howe has resigned as Director and Chief Executive Officer, effective immediately. Kraig Higginson, previously the Chairman of the Board and a former CEO of the company, has been appointed as Interim Chief Executive Officer. The company is actively searching for a permanent CEO. Additionally, Barbara Sher has resigned from her position as Director due to irreconcilable differences with the company's policies and direction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL9NmwxC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2553254904","title":"Aspire Biopharma Holdings Inc. to Launch BUZZ BOMB Pre-Workout Supplement at Major Fitness Conventions, FitCon and FitExpo","url":"https://stock-news.laohu8.com/highlight/detail?id=2553254904","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553254904?lang=en_us&edition=fundamental","pubTime":"2025-07-22 22:46","pubTimestamp":1753195562,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. is set to attend two major fitness conventions, FitCon in Salt Lake City, Utah, on August 1-2, 2025, and FitExpo in Anaheim, CA, on August 2-3, 2025. The company will present its new sublingual pre-workout supplement, BUZZ BOMB, which delivers 50mg of caffeine rapidly to the body. Attendees will receive a sample pack of four different flavors, and company representatives will run \"Feel the Buzz\" contests with BUZZ BOMB t-shirts as prizes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL3hxkQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2550637509","title":"Aspire Biopharma Holdings Inc. to Debut BUZZ BOMB™ at Major Fitness Conventions FITCON and Fit Expo","url":"https://stock-news.laohu8.com/highlight/detail?id=2550637509","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550637509?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:31","pubTimestamp":1752064260,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. is set to attend the FITCON and Fit Expo conventions in early August. At these major fitness events, Aspire will present its new sublingual pre-workout supplement, BUZZ BOMB, allowing over 50,000 attendees to taste, sample, and experience the product's rapid caffeine delivery benefits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDLkhzQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2545282793","title":"Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2545282793","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545282793?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:30","pubTimestamp":1750768247,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025. Aspire Biopharma Holdings, Inc.  has announced the completion of patient dosing in its Phase 1 clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial, conducted in the United States, aims to compare the pharmacokinetic and pharmacodynamic characteristics of the aspirin formulation in healthy volunteers. Topline results from the study are expected to be presented in the middle of the third quarter of 2025. The company plans to use these insights to further discussions with the FDA and to support potential partnership opportunities. Following the trial, Aspire intends to submit a section 505 NDA for approval to market the high-dose aspirin product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL1Y2Sk1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2544970659","title":"Aspire Biopharma Holdings Inc. Unveils Investor Presentation Highlighting Innovative Sublingual Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2544970659","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544970659?lang=en_us&edition=fundamental","pubTime":"2025-06-18 21:11","pubTimestamp":1750252285,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has unveiled its latest investor presentation, highlighting its innovative patent-pending drug delivery technology designed for rapid sublingual absorption. This method allows supplements and other substances to enter the bloodstream swiftly, bypassing the digestive tract and eliminating adverse gastrointestinal reactions. Key highlights include Aspire's lead Rx product, Sublingual Aspirin, and its lead consumer product, BUZZ BOMB. The company is positioned as a mid-stage biotech with several products in development and anticipates first revenues in late 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL285lSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2542231490","title":"Aspire Biopharma Holdings Inc. Appoints Michael C. Howe as New CEO, Succeeding Kraig Higginson","url":"https://stock-news.laohu8.com/highlight/detail?id=2542231490","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542231490?lang=en_us&edition=fundamental","pubTime":"2025-06-10 20:32","pubTimestamp":1749558768,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced that Michael C. Howe will become the new Chief Executive Officer, effective June 10, 2025. Howe, who is currently an Independent Board Member, brings decades of experience from leading brands such as MinuteClinic, Procter & Gamble, and PepsiCo. Kraig Higginson, the outgoing CEO, will transition to the role of Executive Chairman of the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL1nq7rr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","BK4566","LU1868836591.USD","BK4559","BK4585","IE00BLSP4239.USD","LU1894683264.USD","LU1914381329.SGD","LU1280957306.USD","LU0061475181.USD","SG9999015358.SGD","BK4588","LU2552382132.HKD","SG9999001440.SGD","LU0689626769.HKD","IE00BBT3K403.USD","IE00BN8TJ469.HKD","LU1066051498.USD","LU1162221912.USD","LU1929549753.HKD","BK4177","BK4007","SG9999002232.USD","LU0234570918.USD","BK4534","PG","BK4018","LU1894683348.USD","SG9999015341.SGD","LU1066053197.SGD","LU1868837136.USD","IE000M9KFDE8.USD","ASBP","LU1868836757.USD","LU2552382058.USD","LU2129689605.HKD","LU0640476718.USD","LU2097829019.USD","IE00BLSP4452.SGD","LU1585245621.USD","BK4533","LU2242646821.SGD","LU0237698245.USD","LU2129689431.USD","LU1244550494.USD","LU2552382215.SGD","PEP","IE00B3T34201.USD","LU0124676726.USD","SG9999014542.SGD"],"gpt_icon":0},{"id":"2541893062","title":"Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2541893062","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541893062?lang=en_us&edition=fundamental","pubTime":"2025-06-07 05:01","pubTimestamp":1749243686,"startTime":"0","endTime":"0","summary":"Donald G. Fell, a Director of Aspire Biopharma Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL3jdsbj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}]}}